News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Global equity indexes traded flat as investors awaited fresh catalysts.
  • U.S. Treasury yields were little changed, keeping fixed-income markets calm.
  • Dollar held steady against major peers, limiting currency-driven market moves.
  • Oil prices were mostly unchanged, keeping energy-sector volatility low.
  • No central-bank policy actions announced, reducing near-term rate-path uncertainty.
  • No fresh geopolitical escalations reported, keeping risk premiums subdued.

Latest Articles

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Veracyte announced that a retrospective analysis of the phase III NRG/RTOG 0815 trial demonstrates their Decipher Prostate Genomic Classifier can predict which intermediate-risk prostate cancer patients benefit from adding short-term androgen deprivation therapy (ADT) to radiation. Patients with higher Decipher scores saw a significant reduction in…

ZenaTech Reports 425% First Half and 316% Second-Quarter Year-Over-Year Revenue Growth as Drone as a Service Segment Continues to Scale

ZenaTech Reports 425% First Half and 316% Second-Quarter Year-Over-Year Revenue Growth as Drone as a Service Segment Continues to Scale

ZenaTech, Inc. reported a remarkable 316% year-over-year revenue increase in Q2 2026 and a 425% increase in the first half of 2026, primarily fueled by its Drone as a Service (DaaS) segment. The company expanded its geographic footprint through multiple acquisitions and newly opened offices internationally. Investments in AI-powered drone technolog…

Byrna Technologies Launches Media Campaign with iHeartMedia’s “The Bobby Bones Show” to Expand Mainstream Reach

Byrna Technologies Launches Media Campaign with iHeartMedia’s “The Bobby Bones Show” to Expand Mainstream Reach

Byrna Technologies Inc., a Nasdaq-listed personal defense company, has partnered with iHeartMedia's popular The Bobby Bones Show to launch a national media campaign. The campaign includes radio endorsements, podcasts, and digital placements aimed at expanding brand awareness and educating consumers on Byrna’s less-lethal personal safety devices. Th…

Asure Launches AsureCentral to Its Reseller Network, Extending Its Unified Platform to 85,000 More Employers

Asure Launches AsureCentral to Its Reseller Network, Extending Its Unified Platform to 85,000 More Employers

Asure Software has launched its AsureCentral platform to its reseller network, extending access from 30,000 direct employer clients to over 85,000 additional employer clients served by resellers. This integration enables resellers to manage payroll, HR, recruiting, time and attendance, and benefits solutions in a single platform, improving user exp…

Getnet and Nayax Announce Global Strategic Partnership to Accelerate Integrated Payments and Commerce Solutions Across Latin America and Iberia

Getnet and Nayax Announce Global Strategic Partnership to Accelerate Integrated Payments and Commerce Solutions Across Latin America and Iberia

Nayax Ltd and Getnet announced a global strategic partnership to accelerate integrated payments and commerce solutions for unattended business sectors such as vending machines and EV chargers across Latin America and Iberia. The collaboration enables operators to benefit from Nayax's payment technology combined with Getnet's local acquiring network…

Mobilicom Selected to Showcase Resilient Communications for Unmanned Systems at ADS, Inc. ISR Drone Showcase, October 7–8

Mobilicom Selected to Showcase Resilient Communications for Unmanned Systems at ADS, Inc. ISR Drone Showcase, October 7–8

Mobilicom Limited, a Nasdaq-listed provider of cybersecure hardware and software solutions for drones and robotics, announced it will showcase its resilient communication technologies at the ADS ISR Drone Showcase in Virginia. This event attracts U.S. defense leaders and unmanned system operators, positioning Mobilicom to strengthen partnerships an…

21X Seeks U.S. Broker-Dealer Approval to Run ATS for Tokenized Securities; Ray Tierney Named CEO of U.S. Unit

21X Seeks U.S. Broker-Dealer Approval to Run ATS for Tokenized Securities; Ray Tierney Named CEO of U.S. Unit

21X Group has filed for U.S. regulatory permissions to form 21X LLC as a broker-dealer that would operate an alternative trading system (ATS) for trading tokenized securities. The firm has appointed capital markets veteran Ray Tierney to lead U.S. operations as CEO. The move represents 21X Group's first expansion beyond Europe, where its affiliate …

SoundThinking to be Acquired by Transom Capital Group

SoundThinking to be Acquired by Transom Capital Group

SoundThinking, a Nasdaq-listed public safety technology company, has entered into a definitive merger agreement with Transom Capital Group. Shareholders will receive $8.00 per share in cash plus a non-transferable contingent value right (CVR) for up to $3.00 per share based on revenue milestones of its ShotSpotter and SafePointe products. The upfro…

NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs

NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs

PMGC Holdings Inc.'s subsidiary, NorthStrive Biosciences, has partnered with Charles River Laboratories to perform analytical testing on its engineered probiotic programs EL-22 and EL-32. This collaboration aims to strengthen product characterization and manufacturing consistency as these candidates advance toward clinical development, targeting mu…

Beam Therapeutics: Tune Out the AI Chatter, Trade the Clinical Runway

Beam Therapeutics: Tune Out the AI Chatter, Trade the Clinical Runway

Beam Therapeutics (BEAM) has tangible clinical progress in AATD and multiple programs moving into pivotal work. With a market cap near $2.5B, a supportive balance sheet, and visible catalysts, we prefer a mid-term long swing to capture follow-through from clinical data and investor rotation into gene editing—while protecting capital with a defined …

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

Cartesian Therapeutics announced encouraging additional retreatment data for Descartes-08, its investigational CAR-T cell therapy targeting myasthenia gravis (MG). Data from five retreated patients showed sustained and improved symptom relief up to 12 months after retreatment, with a mean 6.6-point reduction in MG-ADL scores. The therapy was well t…

Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia

Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia

Cellectar Biosciences presented data from a subset analysis of its Phase 2 CLOVER WaM trial showing high response rates in Waldenström Macroglobulinemia patients refractory or resistant to BTK inhibitor therapy using iopofosine I 131. The drug demonstrated a major response rate of 79.2%, overall response rate of 87.5%, and duration of response exce…

Optimi Health Appoints Melanie Pump to Board of Directors

Optimi Health Appoints Melanie Pump to Board of Directors

Optimi Health Corp., a publicly traded commercial-stage psychedelic drug manufacturer, appointed Melanie Pump, a seasoned financial executive with 25+ years of experience in technology and emerging companies, to its Board of Directors. The company aims to leverage her expertise as it advances its position in the regulated psychedelic pharmaceutical…

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

Cognition Therapeutics announced a Type C meeting scheduled with the FDA to align on primary endpoints for its planned Phase 3 trial of Zervimesine (CT1812) targeting psychosis symptoms in people with dementia with Lewy bodies (DLB). The company seeks to finalize the trial design focused on hallucinations and delusions and aims to offer a disease-m…

NYSE: MMA – MMA.INC Raises Annualized Cash Operating Cost Reductions to over US$2.51 Million, Accelerating the Path Toward Positive Adjusted EBITDA

NYSE: MMA – MMA.INC Raises Annualized Cash Operating Cost Reductions to over US$2.51 Million, Accelerating the Path Toward Positive Adjusted EBITDA

Mixed Martial Arts Group Limited (NYSE American: MMA), operating as MMA.INC, announced over $800,000 in additional annualized cash operating cost reductions since July 1, 2026, bringing total reductions to over $2.51 million. These reductions stem from technology delivery, AI-supported workflows, and operational discipline, enabling a leaner cost b…

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

Medicus Pharma has submitted an optimized seamless Phase 2b/3 registration-intent protocol for its investigational drug Teverelix®, a next-generation GnRH antagonist, to the FDA. The protocol targets advanced prostate cancer patients at increased cardiovascular risk and aims to create a more capital-efficient, partner-ready development pathway. Thi…

DeFi Technologies’ Subsidiary Valour Launches Zcash (ZEC) ETP

DeFi Technologies’ Subsidiary Valour Launches Zcash (ZEC) ETP

DeFi Technologies Inc., through its subsidiary Valour, has launched the Valour Zcash (ZEC) SEK Exchange Traded Product (ETP) on the Spotlight Stock Market, enabling investors to gain regulated access to the privacy-focused digital asset Zcash via traditional brokerage accounts. This product expands Valour’s portfolio of over 100 digital asset ETPs …

Nu Holdings: User Base Is Huge — The Market Still Undervalues the Growth

Nu Holdings: User Base Is Huge — The Market Still Undervalues the Growth

Nu Holdings has turned explosive user growth into real profitability and cash generation. At roughly $59 billion market cap and trading near $12.25, the stock prices in slower expansion than the company is delivering. This trade idea outlines a long entry, targets and risks for a long-term (180 trading days) position that backs the thesis with rece…